Literature DB >> 16145071

Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors.

Harry E Prince1, Leslie H Tobler, Mary Lapé-Nixon, Gregory A Foster, Susan L Stramer, Michael P Busch.   

Abstract

West Nile Virus (WNV) antibody development and persistence were investigated in blood donors who made WNV RNA-positive (viremic) donations in 2003. Plasma samples from the index donations and follow-up serum or plasma samples were tested for WNV immunoglobulin M (IgM), IgA, and IgG by using enzyme-linked immunosorbent assays. Antibody development was investigated with 154 samples collected from 84 donors 1 to 21 days after their RNA-positive, antibody-negative, index donation. WNV IgM and IgA were first detected on day 3, and all samples collected after day 9 were WNV IgM and IgA positive; WNV IgG was first detected on day 4, and all samples collected after day 16 were positive. Antibody persistence in this donor group (index donations antibody negative) was evaluated by using 128 samples collected from 89 donors on days 22 to 440 of follow-up; 88% of samples were WNV IgM positive, 86% were WNV IgA positive, and 100% were WNV IgG positive. In linear regression analysis, trendlines for WNV IgM and IgA reached the value discriminating positive from negative results at 218 days and 232 days of follow-up, respectively. Similar WNV IgM and IgA persistence trends characterized 27 donors whose index samples were positive for WNV IgM and IgA, as well as 14 donors whose index samples were positive for WNV IgG but negative for WNV IgM. These findings show that WNV IgG emerges after WNV IgM and IgA and that both WNV IgM and IgA typically persist for at least 6 months after infection. Thus, unlike some other flavivirus infections, WNV infection is not characterized by a relatively rapid disappearance of virus-specific IgA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16145071      PMCID: PMC1234148          DOI: 10.1128/JCM.43.9.4316-4320.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection.

Authors:  G Tardei; S Ruta; V Chitu; C Rossi; T F Tsai; C Cernescu
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 2.  West Nile encephalitis.

Authors:  Tom Solomon; Mong How Ooi; David W C Beasley; Macpherson Mallewa
Journal:  BMJ       Date:  2003-04-19

3.  West Nile virus encephalitis.

Authors:  Lyle R Petersen; John T Roehrig; James M Hughes
Journal:  N Engl J Med       Date:  2002-09-23       Impact factor: 91.245

4.  Detection of West Nile virus RNA and antibody in frozen plasma components from a voluntary market withdrawal during the 2002 peak epidemic.

Authors:  L H Tobler; C Bianco; S A Glynn; G B Schreiber; B J Dille; H E Prince; R S Lanciotti; J M Linnen; J Gallarda; V Shyamala; D Smith; S H Kleinman; M P Busch
Journal:  Transfusion       Date:  2005-04       Impact factor: 3.157

5.  Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection.

Authors:  P Koraka; C Suharti; T E Setiati; A T Mairuhu; E Van Gorp; C E Hack; M Juffrie; J Sutaryo; G M Van Der Meer; J Groen; A D Osterhaus
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

Review 6.  West Nile encephalitis: an emerging disease in the United States.

Authors:  A A Marfin; D J Gubler
Journal:  Clin Infect Dis       Date:  2001-10-05       Impact factor: 9.079

7.  Evaluation of a West Nile virus immunoglobulin A capture enzyme-linked immunosorbent assay.

Authors:  Harry E Prince; Mary Lapé-Nixon
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

Review 8.  West Nile virus: a primer for the clinician.

Authors:  Lyle R Petersen; Anthony A Marfin
Journal:  Ann Intern Med       Date:  2002-08-06       Impact factor: 25.391

9.  Laboratory-acquired West Nile virus infections--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-12-20       Impact factor: 17.586

10.  Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases.

Authors:  John T Roehrig; Denis Nash; Beth Maldin; Anne Labowitz; Denise A Martin; Robert S Lanciotti; Grant L Campbell
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

View more
  29 in total

1.  Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines.

Authors:  Melissa N Garcia; Anne M Hause; Christopher M Walker; Jordan S Orange; Rodrigo Hasbun; Kristy O Murray
Journal:  Viral Immunol       Date:  2014-07-25       Impact factor: 2.257

2.  Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing.

Authors:  Konstantinos Tsioris; Namita T Gupta; Adebola O Ogunniyi; Ross M Zimnisky; Feng Qian; Yi Yao; Xiaomei Wang; Joel N H Stern; Raj Chari; Adrian W Briggs; Christopher R Clouser; Francois Vigneault; George M Church; Melissa N Garcia; Kristy O Murray; Ruth R Montgomery; Steven H Kleinstein; J Christopher Love
Journal:  Integr Biol (Camb)       Date:  2015-10-20       Impact factor: 2.192

3.  West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety.

Authors:  Marion C Lanteri; Tzong-Hae Lee; Li Wen; Zhanna Kaidarova; Marjorie D Bravo; Nancy E Kiely; Hany T Kamel; Leslie H Tobler; Philip J Norris; Michael P Busch
Journal:  Transfusion       Date:  2014-06-26       Impact factor: 3.157

4.  Estimation of dengue virus IgM persistence using regression analysis.

Authors:  Harry E Prince; Jose L Matud
Journal:  Clin Vaccine Immunol       Date:  2011-10-26

5.  West Nile virus IgM and IgG antibodies three years post- infection.

Authors:  A Papa; A Anastasiadou; M Delianidou
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

6.  Utilization of follow-up specimens from viremic blood donors to assess the value of west nile virus immunoglobulin G avidity as an indicator of recent infection.

Authors:  Harry E Prince; Mary Lapé-Nixon; Michael P Busch; Leslie H Tobler; Gregory A Foster; Susan L Stramer
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

7.  Diagnosis and management of acute encephalitis: A practical approach.

Authors:  Arun Venkatesan; Romergryko G Geocadin
Journal:  Neurol Clin Pract       Date:  2014-06

8.  Persistence of West Nile virus in the central nervous system and periphery of mice.

Authors:  Kim K Appler; Ashley N Brown; Barbara S Stewart; Melissa J Behr; Valerie L Demarest; Susan J Wong; Kristen A Bernard
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

9.  Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Authors:  A Venkatesan; A R Tunkel; K C Bloch; A S Lauring; J Sejvar; A Bitnun; J-P Stahl; A Mailles; M Drebot; C E Rupprecht; J Yoder; J R Cope; M R Wilson; R J Whitley; J Sullivan; J Granerod; C Jones; K Eastwood; K N Ward; D N Durrheim; M V Solbrig; L Guo-Dong; C A Glaser
Journal:  Clin Infect Dis       Date:  2013-07-15       Impact factor: 9.079

10.  Tregs control the development of symptomatic West Nile virus infection in humans and mice.

Authors:  Marion C Lanteri; Katie M O'Brien; Whitney E Purtha; Mark J Cameron; Jennifer M Lund; Rachel E Owen; John W Heitman; Brian Custer; Dale F Hirschkorn; Leslie H Tobler; Nancy Kiely; Harry E Prince; Lishomwa C Ndhlovu; Douglas F Nixon; Hany T Kamel; David J Kelvin; Michael P Busch; Alexander Y Rudensky; Michael S Diamond; Philip J Norris
Journal:  J Clin Invest       Date:  2009-10-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.